Novel application of chelator-based bone debridement for refractory skull osteonecrosis complicated by Pseudomonas aeruginosa osteomyelitis.
Minghsun Liu, Holly Prentice, Steven Cheng-Han Tsai
PMID 40504488WHAT IT FOUND
A dental EDTA chelator gel softened exposed necrotic skull bone enough for gentle curette removal.
In this single case, greenish necrotic bone disappeared, exposed bone area reduced, and Pseudomonas was absent. Antibiotics were given at the same time. Later, discoloration returned in still-exposed bone.
Key findings
01The applied chelator gel made the necrotic skull bone paste-like and easy to remove with a curette without significant force.
02After five months, the area of exposed bone was reduced by more than 50%, and no greenish necrotic bone remained.
03Pseudomonas aeruginosa, consistently isolated since 2017, was no longer present in cultures while cefepime continued.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a single case report, so it describes what happened to a patient and cannot show that the treatment works for other patients. There was no control group, and the patient received cefepime, chelator gel, xeroform dressing, and curette debridement together, so the contribution of any single component cannot be separated. The patient was immunosuppressed and had multiple comorbidities and prior failed operations, which may have affected healing and may not match other patients. Treatment was paused after five months, and at 11 months greenish discoloration returned in bone that remained exposed, so the result was not fully durable. The paper does not report long-term outcomes, actual wound area measurements, or results for Serratia marcescens.
Declared interests
No conflicts of interest or funding declaration is included in the supplied text.
The easy way to misread this
Do not conclude that chelator-based bone debridement treats refractory skull osteomyelitis in general. This is a single immunosuppressed patient, and cefepime, dressing, curette debridement, and the chelator were given together, so the contribution of any single component cannot be separated.